Molecular structure of Ticagrelor, CAS Number: 274693-27-5
Ticagrelor (CAS 274693-27-5)
Alternate Names:
(1S,2S,3R,5S)-3-[7-[[(1R,2S)-2-(3,4-D1,2-Cyclopentanediolifluorophenyl)cyclopropyl]amino]-5-(propylthio)-3H-1,2,3-triazolo[4,5-d]pyrimidin-3-yl]-5-(2-hydroxyethoxy)-1,2-cyclopentanediol
Application:
Ticagrelor is a reversible antagonist of the platelet purinergic P2Y12 receptor
CAS Number:
274693-27-5
Molecular Weight:
522.57
Molecular Formula:
C23H28F2N6O4S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Ticagrelor is a platelet aggregation inhibitor that functions by reversibly binding to the P2Y12 receptor on platelets, preventing ADP from activating the receptor. This binding inhibits platelet activation and aggregation. At the molecular level, ticagrelor′s mechanism of action involves interfering with the ADP-mediated activation of the P2Y12 receptor, thereby inhibiting the amplification of platelet activation signals. Ticagrelor′s mechanism of action involves modulating platelet function by targeting the P2Y12 receptor, which plays a role in platelet activation and aggregation.
Ticagrelor (CAS 274693-27-5) References
- Is ticagrelor worth its high cost and side-effects? | Guerbaai, RA., et al. 2019. Acta Cardiol. 74: 93-98. PMID: 29730968
- Compared efficacy of clopidogrel and ticagrelor in treating acute coronary syndrome: a meta-analysis. | Wang, D., et al. 2018. BMC Cardiovasc Disord. 18: 217. PMID: 30497387
- Analytical methodologies for the determination of ticagrelor. | Kelemen, H., et al. 2019. Biomed Chromatogr. 33: e4528. PMID: 30836429
- Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week. | Arora, S., et al. 2019. J Am Coll Cardiol. 73: 2454-2464. PMID: 31097167
- Ticagrelor with or without Aspirin after PCI. Reply. | Baber, U., et al. 2020. N Engl J Med. 382: 1076-1077. PMID: 32160679
- Ticagrelor in the management of coronary artery disease. | Loganath, K., et al. 2021. Future Cardiol. 17: 561-571. PMID: 32960097
- An evaluation of ticagrelor for the treatment of sickle cell anemia. | Ribeiro-Filho, J., et al. 2020. Expert Rev Hematol. 13: 1047-1055. PMID: 32972255
- Ticagrelor and omeprazole: A desirable combination in post MI patients? | Alexopoulos, D. 2020. Hellenic J Cardiol. 61: 311-312. PMID: 33181277
- Ticagrelor Use in Stroke Patients: Past, Present, and Future. | Chandra, R., et al. 2021. Vasc Health Risk Manag. 17: 357-362. PMID: 34163168
- Ticagrelor: clinical development and future potential. | Sanderson, NC., et al. 2021. Rev Cardiovasc Med. 22: 373-394. PMID: 34258905
- Ticagrelor. | Kabil, MF., et al. 2022. Profiles Drug Subst Excip Relat Methodol. 47: 91-111. PMID: 35396017
- Ticagrelor and Endothelial Function: An Effect That Persists Far From the Acute Phase and in Monotherapy. | Pavasini, R. and Campo, G. 2022. Arterioscler Thromb Vasc Biol. 42: 799-801. PMID: 35443794
- Association of Dual Antiplatelet Therapy With Ticagrelor With Vein Graft Failure After Coronary Artery Bypass Graft Surgery: A Systematic Review and Meta-analysis. | Sandner, S., et al. 2022. JAMA. 328: 554-562. PMID: 35943473
Inhibitor of:
β thromboglobulin, ADF, BPNT1, CD42a, CD42b, GPVI, OTTMUSG00000019145, P2Y1, P2Y11, P2Y12, P2Y13, P2Y5, P2Y6, P2Y7, PAcP, PECAM-1, PF-4, and TREML1.Activator of:
CES1, P2X5, and P2Y12.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Ticagrelor, 10 mg | sc-472972 | 10 mg | $102.00 | |||
Ticagrelor, 25 mg | sc-472972A | 25 mg | $224.00 | |||
Ticagrelor, 50 mg | sc-472972B | 50 mg | $265.00 | |||
Ticagrelor, 100 mg | sc-472972C | 100 mg | $296.00 |